DES PLAINES, Ill. -
Health care company Abbott Laboratories said Friday it will work with Genentech Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals Inc. to develop a gene test to potentially determine the benefit of a certain lung cancer treatment.
Terms were not disclosed.
Abbott's molecular diagnostics unit will develop the test for Tarceva, an oral tablet used to treat patients with locally advanced or metastatic non-small cell lung cancer that had at least one unsuccessful chemotherapy session.
"By helping to unlock the information found at the molecular level in each person's DNA, we believe that molecular diagnostics hold the promise of personalized medicine," Stafford O'Kelly, Abbott's vice president of molecular diagnostics, said in a statement.
Abbott shares fell 75 cents to $51.34 in morning trading.
No comments:
Post a Comment